<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02235402</url>
  </required_header>
  <id_info>
    <org_study_id>231.336</org_study_id>
    <nct_id>NCT02235402</nct_id>
  </id_info>
  <brief_title>A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients</brief_title>
  <official_title>A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effects of lacidipine on markers of platelet
      activation and other rheological factors in hypertensive patients with those of
      bendrofluazide
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1997</start_date>
  <primary_completion_date type="Actual">March 2000</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in ß-TG (thromboglobulin)</measure>
    <time_frame>Up to week 12 after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in soluble p-selectin</measure>
    <time_frame>Up to week 12 after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rheological factors</measure>
    <time_frame>Up to week 12 after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipid levels between randomisation and last visit</measure>
    <time_frame>Up to week 12 after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinical significant findings in laboratory parameters</measure>
    <time_frame>Up to week 12 after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to week 12 after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Lacidipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bendrofluazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacidipine</intervention_name>
    <arm_group_label>Lacidipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendrofluazide</intervention_name>
    <arm_group_label>Bendrofluazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or over

          -  Hypertensive at screening: Diastolic blood pressure (DBP) 95 - 115 mm Hg and / or
             systolic blood pressure (SBP) &gt;= 160 mm Hg on no therapy or on monotherapy. If
             currently on monotherapy, DBP could have been &lt; 95 mm Hg and SBP &lt; 160 mm Hg, but the
             patient must have been experiencing unacceptable side effects from their current
             treatment. Patient must then be able to stop treatment for the placebo run in phase of
             four weeks without endangering their health (at investigator's discretion)

          -  Hypertensive at randomisation: DBP 95-115 mm Hg and or SBP &gt;=160

          -  Able to give written informed consent

        Exclusion Criteria:

          -  Grad III or grad IV hypertensive retinopathy

          -  Renal impairment; serum creatinine &gt; 150 µmol/L

          -  Heart failure. (New York Heart Association (NYHA) Class III or IV)

          -  Liver impairment (abnormal Liver function test (LFT) with aspartate-amino transferase
             (AST) / alanine-amino transferase (ALT) &gt; 2x upper normal limit or bilirubin &gt; 2x
             upper normal limit)

          -  Recent (&lt; 2 months) history of unstable angina

          -  Recent (&lt; 2 months) history of myocardial infarction

          -  Recent (&lt; 2 months) history of stroke

          -  History of diabetes mellitus or impaired glucose tolerance or random blood glucose &gt;=
             9 mMol/L

          -  Any acute systemic illness or infection

          -  Any severe disease which could interfere with survival or well-being during the study
             (e.g. malignancy)

          -  Patients of child bearing potential

          -  Current or previous drug and / or alcohol abuse

          -  Severely limited venous access

          -  Haemoglobin &lt; 10g/dL (male patients), haemoglobin &lt; 9g/dL (female patients)

          -  Requirement for anticoagulant therapy

          -  Severe valvular heart disease (investigator's discretion)

          -  Atrial fibrillation or other serious cardiac dysrhythmia

          -  History of thyroid disease or abnormal thyroid function test (thyroid stimulating
             hormone (TSH) &lt; 0.4 mU/L or &gt; 5.4 mU/L)

          -  History of connective tissue disorder

          -  Concurrent participation in any other clinical trial or participation within two
             months enrolment

          -  Requirement for restricted drugs

          -  Patients currently on treatment with lacidipine or bendrofluazide (BNFZ)

          -  Patients unable to attend clinics

          -  Any clinical condition which in the opinion of the investigator, would preclude the
             safe fulfillment of the protocol and the safe administration of trial medication

          -  Seated blood pressure (BP) exceeding either 210 mm Hg (systolic) or 115 mm Hg
             (diastolic) at screening or randomization

          -  Standing BP &lt; 140 mm Hg (systolic) and &lt; 95 mm Hg (diastolic) at randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2014</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacidipine</mesh_term>
    <mesh_term>Bendroflumethiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

